TG Therapeutics Inc (USD)
TGTX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range19.75 | 20.76
52-Wk Range- | -
Last Close20.09
Mkt Cap (m)2,304.40
Dividend yield-
ISINUS88322Q1085
Volume1,645,855.00
Exchange VenueNAS

Company Profile

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Key Information
Price/Earning-
Price/Book0.00
Price/Sales12,482.33
P/CF-
Rev Growth (3 year avg)-0.08
EPS Growth (3 year avg)-
Operating Margin % -111,220.39
Net Margin %-113,730.92
Return on Equity-551.85
Debt/Equity1.06

Documents

Prospectus
en 18/05/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.tgtherapeutics.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.150.150.150.150.150.15
Operating Income (m)-55.72-63.18-78.97-118.71-174.40-169.06
Net Income (m)-55.78-62.95-78.25-118.48-173.48-172.87
Basic EPS-1.64-1.38-1.60-1.91-2.30-1.96
Avg. Diluted Shares Outstanding (m)34.0745.6549.0462.0775.4788.37
Balance Sheet
USD201420152016201720182019
Current Assets (m)85.2286.8750.8693.3279.03149.15
Non Current Assets (m)1.5326.603.924.064.5913.86
Total Assets (m)86.75113.4754.7897.3883.62163.01
Current Liabilities (m)5.1210.5316.8827.9638.8584.45
Total Liabilities (m)------
Total Equity (m)80.10101.5735.8766.9924.0438.62
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-35.06-44.69-61.59-93.76-128.93-132.81
Capital Expenditure (m)-0.02-0.04-0.340.00-0.09-0.13
Figures are quoted in USD unless stated otherwise
-
No change
$
20.09
Last Price